D9319C00001- 1L OC Mono Global RCT

NCT04884360 | Active Not Recruiting Phase 3

• 2 other identifiers: D9319C000012020-005960-68
• Study Type: interventional
• Target: 366
• Locations: 10 countries
• Sites: 89

Brief Summary

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or partial response following treatment with standard first-line platinum-based chemotherapy.

Conditions

Ovarian Cancer

Keywords

BRCA Wild Type;; Double-blind;; Randomized;; Placebo-controlled;

Outcome Measures

Primary Outcomes (2)

• Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment.

  PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause.

  Approximately 3 years

• Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard 1st line platinum-based chemotherapy treatment.

  PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by the investigator at the local site, or death due to any cause.

  Approximately 3 years

Secondary Outcomes (14)

• Superiority of olaparib as maintenance treatment relative to placebo by assessment of OS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard first line platinum based chemotherapy treatment.

  Approximately 4 years

• Superiority of olaparib as maintenance treatment relative to placebo by assessment of OS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard first-line platinum-based chemotherapy treatment.

  Approximately 4 years

• Superiority of olaparib as maintenance treatment relative to placebo by assessment of TFST in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum-based chemotherapy treatment.

  Approximately 4 years

• Superiority of olaparib as maintenance treatment relative to placebo by assessment of TFST in participants with a BRCAwt tumour and a CR or PR following standard first line platinum based chemotherapy treatment.

  Approximately 4 years

• Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS2 in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.

  Approximately 4 years

Other Outcomes (1)

• Assess the safety and tolerability of olaparib in terms of AEs/SAEs as compared with placebo in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum-based chemotherapy treatment.

  Approximately 3 years

Study Arms (2)

Group A: Olaparib tablets 300 mg oral twice daily (n=238).

EXPERIMENTAL

Participants in Group A will receive olaparib tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.

Drug: Olaparib

Group B: Placebo tablets 300 mg oral twice daily (n=118)

PLACEBO COMPARATOR

Participants in Group B will receive matching placebo tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.

Other: Matching placebo

Interventions

Matching placebo OTHER

Matching placebo tablets taken orally at a dose of 300 mg twice daily

Group B: Placebo tablets 300 mg oral twice daily (n=118)

Olaparib DRUG

Olaparib tablets 300 mg oral twice daily

Group A: Olaparib tablets 300 mg oral twice daily (n=238).

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants must be ≥18 years at the time of (pre-)screening
• Histological and staging criteria:Female participants who must have histologically newly diagnosed high-grade serous or high-grade endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is Stage III or IV according to the International FIGO 2014.
• Participants are eligible if they fulfil any of the following surgical criteria:
• Stage III: primary debulking surgery with macroscopic residual disease post-surgery, neoadjuvant chemotherapy, or inoperable.
• Stage IV: primary debulking surgery regardless of residual disease, neoadjuvant chemotherapy, or inoperable.
• Chemotherapy criteria:
• Participants must have received platinum-based chemotherapy consisting of a minimum of 6 treatment cycles and a maximum of 9, however, if platinum-based therapy must be discontinued early as a result of toxicities specifically related to the platinum regimen, participants must have received a minimum of 4 cycles of the platinum regimen.
• A participant who received interval debulking surgery must have had ≥ 2 postoperative cycles of platinum-based therapy.
• Participants must meet one of the criteria specified below for pre-treatment CA-125 measurements as follows:
• CA-125 in the normal range or
• CA-125 decrease by ≥ 90% during their front-line therapy that is stable for at least 7 days (ie, no increase \> 15% from nadir). During screening, if the first CA-125 value is greater than the upper limit of normal (ULN), a second assessment must be performed at least 7 days after the first. If the second assessment is \> 15% more than the first value, the participant is not eligible).
• Participants should not have received bevacizumab with first-line chemotherapy or be planned to receive bevacizumab maintenance therapy.
• Participants must be randomised within a maximum of 12 weeks from the last day of chemotherapy infusion (but no earlier than 3 weeks).
• \. ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to randomisation.
• , Provision, at pre-screening, of a formalin-fixed, paraffin-embedded (FFPE) tumour sample to assess tBRCA status and for HRD testing centrally. The centrally performed tBRCA test results must be available prior to randomisation and must indicate that the participant has a BRCAwt tumour, defined by the absence of a deleterious or suspected deleterious BRCA mutation by central testing.

You may not qualify if:

• , Participants with stable disease or progressive disease on the post-treatment scan or clinical evidence of progression at the end of the participant's first-line chemotherapy treatment, or any evidence of progressive disease prior to randomization.
• , Participant has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma, undifferentiated ovarian cancer, non-epithelial ovarian cancer, borderline tumours or low grade epithelial ovarian tumours (applies to fallopian tube and primary peritoneal tumours where applicable).
• , Participants with Stage III disease who have had complete cytoreduction (ie, no macroscopic residual disease) at their primary debulking surgery.
• , Participants who have undergone ˃ 2 debulking (cytoreductive) surgeries.
• , History of another primary malignancy except for: malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence; Adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), and Stage 1, Grade 1 endometrial carcinoma. Participants with a history of localised triple negative breast cancer, provided they completed their adjuvant chemotherapy more than three years prior to registration, and that the participant remains free of recurrent or metastatic disease.
• , Persistent toxicities (CTCAE Grade ≥2) caused by previous anticancer therapy, excluding alopecia and CTCAE Grade 2 peripheral neuropathy. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included after consultation with the AstraZeneca study physician.
• , Participant is immunocompromised
• , Prior exposure to a PARP inhibitor, including olaparib
• , Any concurrent anticancer treatment
• , Currently pregnant or breast-feeding

Sponsors & Collaborators

• AstraZeneca: lead

Study Sites (89)

Research Site

Santiago, 8241479, Chile

Location

Research Site

Santiago, 8420383, Chile

Location

Research Site

Temuco, 4800827, Chile

Location

Research Site

Temuco, 4810218, Chile

Location

Research Site

Viña del Mar, 2540488, Chile

Location

Research Site

Baoji, 721008, China

Location

Research Site

Beijing, 100034, China

Location

Research Site

Beijing, 100142, China

Location

Research Site

Changchun, 130021, China

Location

Research Site

Changsha, 410013, China

Location

Research Site

Chengdu, 610041, China

Location

Research Site

Chengdu, 610072, China

Location

Research Site

Chongqing, 400038, China

Location

Research Site

Chongqing, 400042, China

Location

Research Site

Guangzhou, 510095, China

Location

Research Site

Guangzhou, 510120, China

Location

Research Site

Guiyang, 550004, China

Location

Research Site

Haikou, 570311, China

Location

Research Site

Hangzhou, 310022, China

Location

Research Site

Hefei, 230001, China

Location

Research Site

Hefei, 230601, China

Location

Research Site

Jiaxing, 314001, China

Location

Research Site

Jining, 272029, China

Location

Research Site

Lanzhou, 730030, China

Location

Research Site

Linyi, 276000, China

Location

Research Site

Nanjing, 210009, China

Location

Research Site

Qingdao, 266034, China

Location

Research Site

Rui’an, 325200, China

Location

Research Site

Shanghai, 200011, China

Location

Research Site

Shanghai, 200032, China

Location

Research Site

Shenyang, 110042, China

Location

Research Site

Suzhou, 215004, China

Location

Research Site

Tianjin, 300050, China

Location

Research Site

Tianjin, 300060, China

Location

Research Site

Ürümqi, 830000, China

Location

Research Site

Ürümqi, 830054, China

Location

Research Site

Wenzhou, 325027, China

Location

Research Site

Wenzhou, CN-325000, China

Location

Research Site

Wuhan, 430000, China

Location

Research Site

Wuhan, 430022, China

Location

Research Site

Wuxi, 214062, China

Location

Research Site

Xuzhou, 221000, China

Location

Research Site

Xuzhou, 221009, China

Location

Research Site

Yanji, 133000, China

Location

Research Site

Zibo, 255200, China

Location

Research Site

Zunyi, 563100, China

Location

Research Site

Bogotá, 110221, Colombia

Location

Research Site

Bogotá, Colombia

Location

Research Site

Medellín, 50030, Colombia

Location

Research Site

Gūrgaon, 122001, India

Location

Research Site

Jaipur, 302017, India

Location

Research Site

Kolkata, 700160, India

Location

Research Site

Madurai, 625107, India

Location

Research Site

Namakkal, 637001, India

Location

Research Site

Nashik, 422002, India

Location

Research Site

New Delhi, 110085, India

Location

Research Site

New Delhi, 11029, India

Location

Research Site

Arequipa, AREQUIPA01, Peru

Location

Research Site

Lima, 15036, Peru

Location

Research Site

Lima, LIMA 29, Peru

Location

Research Site

Lima, LIMA 34, Peru

Location

Research Site

San Isidro, 27, Peru

Location

Research Site

Arkhangelsk, 163045, Russia

Location

Research Site

Chelyabinsk, 454087, Russia

Location

Research Site

Moscow, 115478, Russia

Location

Research Site

Moscow, 117997, Russia

Location

Research Site

Saint Petersburg, 197758, Russia

Location

Research Site

Saint Petersburg, 198255, Russia

Location

Research Site

Tomsk, 634028, Russia

Location

Research Site

Yekaterinburg, 620905, Russia

Location

Research Site

Port Elizabeth, 6045, South Africa

Location

Research Site

Adana, 01120, Turkey (Türkiye)

Location

Research Site

Ankara, 06100, Turkey (Türkiye)

Location

Research Site

Ankara, 06800, Turkey (Türkiye)

Location

Research Site

Cordaleo, 35575, Turkey (Türkiye)

Location

Research Site

Istanbul, 34010, Turkey (Türkiye)

Location

Research Site

Samsun, 55139, Turkey (Türkiye)

Location

Research Site

Chernihiv, 14029, Ukraine

Location

Research Site

Dnipro, 49102, Ukraine

Location

Research Site

Ivano-Frankivsk, 76018, Ukraine

Location

Research Site

Kharkiv, 61103, Ukraine

Location

Research Site

Kryvyi Rih, 50048, Ukraine

Location

Research Site

Kyiv, 03022, Ukraine

Location

Research Site

Kyiv, 04050, Ukraine

Location

Research Site

Zaporizhzhia, Ukraine

Location

Research Site

Hanoi, 100000, Vietnam

Location

Research Site

Hà Nội, 100000, Vietnam

Location

Research Site

Ho Chi Minh City, 700000, Vietnam

Location

Research Site

Ho Chi Minh City, Vietnam

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

olaparib

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Xiaohua Wu

  Fudan University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 20, 2021
• First Posted: May 13, 2021
• Study Start: May 31, 2021
• Primary Completion (Estimated): July 27, 2026
• Study Completion (Estimated): July 27, 2027
• Last Updated: March 2, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Locations

RU (8); PE (5); VN (4); CL (5); CN (41); CO (3); UA (8); IN (8); ZA (1); TU (6)